Patronage & Patnership
Home  /  Patronage & Patnership
spacer
spacer

Patronage & Patnership

The starting point in 2007 was the collaboration of a nonprofit Association (Association for the Prevention of the Cardiometabolic Risk APRC founded by Claude VINCENT in 2004) with the French Academy of Medicine to organize symposia on the theme of chronic diseases: Metabolic syndrome, diabetes and prescriptions, therapeutic patient education, bariatric surgery and obesity and since 2015 microbiome. The 1st World Academic Colloquium on Microbiome was held in Paris in October 2017 with the main leaders of the many disciplines involved in microbiome. On this occasion a collaboration was established with IHMC (International Human Microbiome Consortium)

On this occasion the World Organization of the Academies of Health (IAP for Health) also gave its the patronage as well as for the 2019-2025 program. At the same time, various representatives of the Academies of Medicine participated in the 2017 Colloquium: USA, China, Belgium, Germany. The French Academy of Sciences joined the IAG microbiome in 2019 and other Academies where researchers exist will be added in 2019 Italy, Spain, Netherlands Ireland Denmark and Canada

 

Partnership

the Academies by status have not generated revenue to carry out external studies, so the APRC provides this funding through partnerships with Industrialists. The partnership needs must cover operating expenses and enough to finance the 3 project managers and current expenses.

This partnership covers the period 2019-2021 where the costs are modest compared to the importance of the objective.

In the second period 2021-2025, the costs of carrying out studies are significant and require the intervention of States (EU, US, China...) by entering existing programs dedicated to microbiome, it will also be called upon the major Foundations. Then, when the Funds have been released, calls for tenders will be launched for studies to be carried out by academic and industrial researchers.

In addition to financing, the role of industrialists is to advise the WGs on:

  • the purpose of the research so that it is viable in the reality of a diagnosis or treatment,
  • industrial constraints on active ingredients and pharmaceutical form,
  • regulatory requirements for drug and foods,
  • cost and mass production constraints for non-drug products.

The objective is to create a real cooperation between academic R&D and the private sector in order to maximize the value of public investment so that it can be transformed into an improvement of Public Health and economic improvement of the Nations

the partners of the first World Academic Colloquium in 2017 in Paris were

Ethics Structures

In order to preserve the high ethical value of the Academies, structures and managers have been set up

Claude Jaffiol (Chairman) and Jacques Bringer, Patrice Debré (Academicians)

Direction of the IAG microbiome Philippe Sansonetti (chairman and representative of the French Medicine  Academy ) Joel Doré (director of INRA)

President of the APRC Claude Vincent who guarantees an organization in line with academic ethics

Patronage

 
IAP Science Health Policy «the interacademy partnership»

Achieving ‘Good Health and Well-being’ for all is the third Sustainable Development Goal. Health, however, is a transdisciplinary issue and goes beyond just ‘medicine’.

Within IAP, activities relating to improving global health are dealt with primarily by IAP for Health - a network of the world’s national medical academies and academies of science and engineering with medical sections. Currently there are 78 members.

The goals of the IAP for Health are: to strengthen the capacity of academies to provide evidence based advice to governments on health and science policy; to support the creation of projects by member academies to strengthen health research and higher education in their countries; and to issue consensus statements on matters of importance to global health.

Institut de France, Académie des Sciences

Since its creation, the Academy has been dedicated to the development of science and advises government authorities in this field.

This dual vocation has been reinforced over time as knowledge has evolved. Today, academics carry out their missions, towards the State and towards foundations, within committees or working groups set up by the Academy.

  • Encouraging scientific life
  • Promoting science education
  • Transmit knowledge
Académie Nationale de Médecine

According to its statutes, the National Academy of Medicine is responsible for responding to government requests on any matter concerning public health and for all research objects that can contribute to the advancement of the art of healing.

The Royal Ordinance of 20 December 1820 defines its missions:

«This Academy will be specially established to respond to government requests on all matters of public health, and mainly on epidemics, diseases, specific to certain countries, epizootics, various cases of forensic medicine, the spread of vaccinia, the examination of new remedies and secret remedies, both internal and external, natural or artificial mineral waters.

It will deal with all objects of study or research that can contribute to the progress of the different branches of the art of healing. »

The company brings together physicians, surgeons, biologists, pharmacists and veterinarians recognized for their scientific work and for the responsibilities they have assumed in the health field.

Since its inception, the Academy has had eleven national Nobel Prize Laureate members. Its independence and the relevance of its reports and communications give it an original place and an important role in the health field.

It may be asked for an opinion by the public authorities but it may also take its own initiative in the fields of health but more willingly on questions of public health and medical ethics.

Industrial Partnership

 

Key premium partner

Fering

Major partner

Prefired partner

Annual partner

Foundation partnership

 

Key foundation partner

Major foundation partner

Foundation partner

Start up partnership

 

Collaborating start up partner

LNC Therapeutics

Between 2010 and 2017, LNC focused exclusively on developing medical nutrition products. This work led to the development of Stablor®.

The demonstration of its clinical efficacy in visceral fat loss and cardiometabolic risk factors in obese patients with metabolic syndrome.

The trial also highlighted Stablor®’s role in modulating the gut microbiome, and more specifically its effect on a family of bacteria known for its anti-obesity potential, thus opening up an array of new opportunities for the company.

In 2018, based on this data, a new management team sparked a new strategic plan aiming to harness the potential of LNC science and focused on innovative gut microbiome-based drug discovery.

MAAT Pharma

We are a clinical stage oncology company and industry leader in microbiome restoration therapy which has demonstrated safety and restoration of both immune homeostasis and gut barrier integrity in a Phase 1a/2b trial in AML patients.

As an initial focus, we are committed to improving overall survival in blood cancers and graft-versus-host disease. We have established the MMRB (MaaT Microbiome Restoration Biotherapeutics) integrative platform to develop our lead product, determine novel disease targets and identify biomarkers for microbiome-related conditions.

We benefit from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Exeliom Bioscience

Exeliom is a preclinical-stage biopharmarceutical company whose mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives.

We are committed to developing the next generation of probiotics: innovative microbial therapies.

We will use our breakthrough translational approach, our unique relationships with our partners and our passion to devise new ways to prevent and treat diseases.

Our values shape the big and small decisions we make everyday, and the relationships we build and nurture within and outside the company. We may succeed. We may fail.

But, by working together, with integrity and respect, we will always be doing things the right way, and we just might achieve something that others may not believe possible.

Start up partner

APRC microbiome © 2026 - all rights reserved     term and conditions created by Influa © agence de référencement
What is your position